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Condensation: COSGROVE has identified which 22 core outcomes should be included in all 
future trials in fetal growth restriction. 
Short Title: COSGROVE- Core Outcome Set for Fetal Growth Restriction 
AJOG at a Glance:  
A.Why was this study conducted?  
Systematic evaluation of the evidence from clinical trials is often difficult because of 
variation in the outcomes measured and reported. The development and implementation of 
core outcome sets for use in clinical trials improves the efficiency of trials, minimizes 
research waste and reporting bias - and ultimately ensures that evidence is readily available 
for policy and practice. 
B. What are the key findings?  
The COSGROVE study identified 22 outcomes grouped under four domains: maternal (n=4); 
fetal (n=1); neonatal (n=12), and childhood (n=5), that should be measured and reported in 
all future trials of prevention or treatment of fetal growth restriction. 
C. What does this study add to what is already known?  
This core outcome set for fetal growth restriction will enable future trials to measure 
similar, meaningful outcomes, and ensure findings from different studies can be compared 
and combined. 
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Abstract 
Background Fetal growth restriction refers to a fetus that does not reach its genetically 
predetermined growth potential. It is well recognized that growth restricted fetuses are at 
increased risk of both short and long-term adverse outcomes. Systematic evaluation of the 
evidence from clinical trials of fetal growth restriction is often difficult because of variation 
in the outcomes measured and reported. The development of core outcome sets for fetal 
growth restriction studies would enable future trials to measure similar, meaningful 
outcomes 
Objective To develop core outcome sets for trials of prevention or treatment of fetal growth 
restriction.  
Study Design Delphi consensus study. 
Population An international group of health care providers, researchers, academics and 
maternity service users with informed opinions or known expertise in fetal growth 
restriction . 
Methods A comprehensive literature review was conducted to identify outcomes reported 
in studies of prevention or treatment of fetal growth restriction. All outcomes were 
presented for prioritization to key stakeholders (135 health care providers, 68 
researchers/academics and 35 members of the public) in three rounds of online Delphi 
Surveys. A priori consensus criteria were used to reach agreement on the final outcomes for 
inclusion in the core outcome set at a face-to-face meeting with five health care providers, 
five researchers/academics and six maternity service users. 
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Results In total, 22 outcomes were included in the final core outcome set. These outcomes 
were grouped under four domains: maternal (n=4); fetal (n=1); neonatal (n=12), and 
childhood (n=5). 
Conclusions The COSGROVE study identified a large number of potentially relevant 
outcomes and then reached consensus on those factors that – as a minimum – should be 
measured and reported in all future trials of prevention or treatment of fetal growth 
restriction. This will enable future trials to measure similar, meaningful outcomes, and 
ensure findings from different studies can be compared and combined.  
Key words Fetal growth restriction, Small for Gestational Age, pregnancy, trials, 
randomised, newborn, mortality, morbidity, core outcomes. 
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Introduction 
Fetal growth restriction (FGR) is a condition of suboptimal growth of the fetus in utero with  
heterogeneous causes. It is associated with increased risks of perinatal morbidity and  
mortality, including fetal hypoxia, birth asphyxia, prematurity, stillbirth and neonatal death 
(1) (2). Long after birth with FGR, this group of infants is at higher risk of poor growth, 
metabolic and cardiovascular disorders and neurodevelopmental delay (3) (4). The scientific 
community has undertaken detailed research into the causes, consequences, prediction and 
prevention of FGR. However, these efforts have been impeded by a lack of consensus on the 
diagnosis of FGR; what exposure variables should be measured; and what outcomes 
collected (5). Thus, although interventions for preventing and treating FGR have been 
studied, the resulting evidence is often difficult to interpret because of differences in 
inclusion, case selection, definitions and reporting of outcomes. Such heterogeneity results 
in difficulties not only of direct comparisons between studies, but also renders aggregating 
data amongst trials difficult. This means that evidence synthesis and meta-analysis is 
unsatisfactory. This in turn limits the reliability of evidence to guide health care decisions.  
These challenges could be mitigated if it was possible to agree, in advance, what study data 
should be collected. We have previously reported on a consensus procedure for the 
antenatal diagnosis of FGR (6), the diagnosis of FGR in the newborn period (7), and a 
minimum reporting set of study variables for FGR research studies (8). In this study we aim 
to develop consensus among international stakeholders on a set of core outcomes that 
should be used in trials that evaluate (a) preventative or (b) therapeutic interventions for 
FGR. COS represent an agreed standard set of outcomes that should be measured and 
reported, as a minimum, in all clinical trials in specific areas of healthcare; they are also 
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suitable for use in cohort studies, clinical audit, and other research methods (9). By 
standardizing a minimum set of outcomes across trials the potential for evidence synthesis 
is maximized, and this improves the efficiency of trials, minimizes research waste and 
reporting bias - and ultimately ensures that evidence is readily available for policy and 
practice.  
 
Methods 
The protocol of the COSGROVE study (Core Outcome Set for GROwth restriction; 
deVeloping Endpoints), is described in detail elsewhere (10). In brief, in order to build 
consensus from relevant stakeholders, a systematic review of outcomes was first conducted 
to identify all potential outcomes collected in studies of FGR. Following this, the outcomes 
identified were presented to stakeholders for prioritization in a modified Delphi study. 
Finally, the prioritized list of outcomes was discussed in a face-to-face meeting and 
consensus reached on which outcomes would be included in the final COS. Two separate 
procedures were initially conducted – one for prevention and another for treatment of FGR; 
however, the results from these separate consensus procedures were almost identical, and 
suggested that combining the two was appropriate; therefore a single COS was created. 
The design was guided by The Core Outcome Set-STAndards for Development (COS-STAD) 
(11). We report the findings of the COSGROVE study in accordance with the COS-STAR 
Statement reporting criteria (12) and guidance from The COMET (Core Outcome Measures 
in Effectiveness Trials) Initiative (13). The study was registered prospectively with COMET 
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(registration number 689, available online at http://www.comet-
initiative.org/studies/details/689/).  
 
Identification of relevant outcomes 
We conducted a comprehensive search of the published literature including previous trials 
and systematic reviews of trials to identify potential outcomes. We searched the Cochrane 
Central Register of Controlled Trials, EMBASE, and Medline from inception to June 2017 for 
randomised controlled trials and systematic reviews evaluating any potential intervention 
for prevention or treatment of FGR. The review highlighted a significant lack of 
standardization in what outcomes are measured and reported. The outcomes from this 
review were grouped into the following domains: maternal; fetal; neonatal; childhood, and 
patient reported quality of life, with sub-categories as appropriate.   
Participants 
In order to reflect the perspectives of a variety of international stakeholders with informed 
opinions or known expertise in FGR, we accessed potential participants through mass 
invitational emails, electronic discussion lists, professional organizations and social media. 
Invitees were encouraged to forward the invitation to others who they regarded as having 
appropriate experience to capture as broad expertise as possible.  We used purposeful 
sampling to approach eight groups of stakeholders: 1) users of maternity services (women 
and their partners) or their representative advocacy group; 2) midwives; 3) obstetricians; 4) 
pediatricians/neonatologists; 5) family doctors; 6) ultra-sonographers; 7) policy makers, and 
8) individuals with specific expertise/interest in research or perinatal care related to FGR. 
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These groups were later combined into 3 groups: health care providers; 
researchers/academics, and maternity service users. This was done to present findings by 
stakeholder groups in the Delphi Manager platform (http://www.comet-
initiative.org/delphimanager/) used for the COS development.  We provided potential 
participants with an explanatory email and a video (https://youtu.be/yqAvHJcs2Rg) 
outlining the need for the study, the principles of a COS and participant involvement. 
Individuals who wished to participate were then asked to click on a link to register for the 
study and indicate their consent to receive the Delphi survey. 
Ethical approval for the study was obtained from the Medical Ethics Review Committee of 
the University of Groningen.  
 
Modified Delphi Study 
We conducted a 3-round modified Delphi study using the web based DelphiManager system 
(http://www.comet-initiative.org/delphimanager/). Each round had a response closing date 
21 days after the date of distribution of the survey, with regular email reminders to non-
responders. A short questionnaire seeking relevant participant demographic data including 
stakeholder group and country of residence was presented in the first round. 
The round 1 survey presented the outcomes identified in the review. Each outcome was 
explained in plain English using explanations from patient information leaflets where 
available. Participants were asked to rate each outcome for FGR prevention and treatment 
separately on a 9-point Likert-scale, with higher values representing increased importance 
for inclusion in the COS, or to select an ‘unable to score’ category. Participants were given 
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the option to add up to two further ‘new’ outcomes that they considered important or 
relevant for inclusion in COS (13). Only participants who had completed the first round were 
invited to participate in round 2. 
The round 2 survey presented all outcomes from round 1 again. In round 2, in addition to 
presenting each participant’s individual round-1 score, results for each separate stakeholder 
group were also presented numerically as proportions. Using the same 9-point Likert scale, 
round 2 participants were then asked to re-rate each outcome taking into consideration 
their own initial response and the responses from the separate stakeholder groups. At this 
point, participants were also asked if they would be able and willing to attend a subsequent 
planned face-to-face consensus meeting. Only those participants who had completed 
rounds 1 and 2 were invited to participate in round 3. 
In round 3, survey participants were presented with outcomes from round 2 that were rated 
as important for inclusion, defined as scoring 7-9 on Likert scale by at least 70% of all 
respondents and rated as of limited importance (1-3 on Likert scale) by 15% or less of all 
respondents. These consensus criteria for round 3 were decided a priori based on the total 
number of outcomes remaining after round 2, and on guidance in The COMET Handbook 
(13) and COS-STAD (11). 
Following round 3 outcomes were then classified as ‘consensus in’ (≥70% participants 
scoring as 7–9 and <15% scoring as 1–3), ‘consensus out’ (≥70% scoring as 1–3 and <15% 
scoring as 7–9) or ‘no consensus’ (anything else). We agreed our consensus criteria for 
inclusion a priori based on guidance in The COMET Handbook (13) and COS-STAD (11). 
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Consensus meeting 
Consensus on the final outcomes to be included in the COS was achieved through a face-to-
face full day meeting on April 18
th
 2018 in Brighton UK. The meeting was moderated by an 
independent chair (JK) and the consensus panel comprised sixteen participants, from a 
variety of countries, representing the stakeholder groups who had volunteered in their 
Delphi survey or who had been purposefully sampled for their expertise by the COSGROVE 
working group. They were maternity service users (n=6), healthcare providers including 
midwives, obstetricians, neonatologists and family physicians (n=5) and 
researchers/academics in FGR (n=5). All participants were asked to vote on each outcome as 
‘yes’ or ‘no’ for inclusion in the final COS following a period of discussion on each listed 
outcome. The consensus criterion used at the meeting to determine whether an outcome 
should be in the final COS was defined as 70% or more of the consensus meeting 
participants scoring it ‘yes’. The participants were also asked to consider whether each 
outcome was uniquely a prevention outcome, uniquely a treatment outcome or an outcome 
for both prevention and treatment. Anonymous voting was facilitated by participants using 
Poll Everywhere (www.polleverywhere.com). Members of the COSGROVE working Group 
attended as observers only. 
Results 
The review of the literature identified 238 different outcomes for prevention and treatment 
of FGR (14). Following the removal of duplicate outcomes, the combination of similar 
outcomes and the clarification of outcome terminology by the COSGROVE team, 103 
outcomes remained. For example: cord pH arterial, cord PO2 arterial, cord PCO2 arterial, 
cord BE arterial, cord pH venous, cord PO2 venous, cord PCO2 venous and cord lactate all 
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became the outcome ‘Umbilical cord blood gases’. Grouping different outcome assessments 
into a single category referring to an outcome in this manner is recommended in the COMET 
Handbook (13) as is the subsequent classification of those outcomes under overarching 
domains. We considered using the taxonomy of outcomes discussed by Dodd et al (15) but 
found that the domains maternal, fetal, neonatal, childhood and patient-reported, with 
appropriate subdomains, were more appropriate to our needs. As there was significant 
overlap in the outcomes for prevention and treatment, we decided to present the 103 
outcomes twice in the round 1 Delphi survey; participants were asked to rate them from a 
prevention perspective first and then from a treatment perspective. 
Two hundred and thirty eight relevant stakeholders from 36 different countries registered 
to participate in COSGROVE and received the first survey. The round 1 survey was 
completed by 180 people (76%), of whom 59% (n=105) were health care providers, 29% 
(n=53) were researchers/academics and 12% (n=22) were maternity service users.  
The round 2 survey again presented the 103 outcomes twice. Some new outcomes had been 
suggested by participants in round 1. After evaluation these were all judged to be either 
covered by the outcomes presented already or suggested by one person only; therefore, in 
keeping with the a priori decisions in the study protocol (10), no new outcomes were added 
after round 1. Round 2 was completed by 65% (118/180) of those who had completed the 
first survey: 58% (n=69) health care providers, 36% (n=42) researchers/academics and 6% 
(n=7) maternity service users. At the end of round 2, the number of outcomes was reduced 
by applying our pre-specified consensus criteria.  
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The round 3 survey presented 34 prevention outcomes and 35 treatment outcomes for 
rating. Round 3 was completed by 91% (107/118) of those who had completed the second 
survey. The stakeholder groups represented in the 3
rd
 round were 59% (n=63) health care 
providers, 35% (n=37) researchers/academics and 6% (n=7) maternity service users. At the 
end of round 3, we again applied a priori consensus criteria to decide which outcomes to 
bring forward to the consensus meeting. As no outcome met the criteria for “consensus 
out”, 34 prevention outcomes and 35 treatment outcomes were brought forward for 
discussion at the face-to-face consensus meeting. 
Following the consensus meeting 22 outcomes were included in the final COS for the 
treatment or prevention of FGR, under four domains: maternal (n=4); fetal (n=1); neonatal 
(n=12), and childhood (n = 5). Given almost complete overlap, the consensus panel 
participants concluded that all 22 outcomes were suitable for both prevention and 
treatment; consequently a single COS for the prevention and/or treatment of FGR was 
arrived at (Table 1). Outcomes that were removed or combined following discussion (e.g. 
stillbirth and intrapartum death were combined into stillbirth) are listed in Supplementary 
table 2 (S2). 
 
Table 1: Final COS to be included in all studies of FGR 
Discussion 
Main Findings 
COSGROVE developed a COS for FGR using robust consensus methodology to capture the 
views and opinions of an international group of multiple stakeholders, including patients. 
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The final COS includes 22 outcomes grouped under four domains. It is important that a COS 
represents the minimum number of outcomes that should be reported in all trials in a 
specific area. The list is not exhaustive and additional outcomes can be freely reported if 
deemed relevant (9). The list is suitable not only for trials but also for cohort studies, studies 
of diagnostic accuracy or service evaluation.  
Our effort is an international collaboration between research groups aiming to standardize 
research, monitoring and management for FGR. There is a growing recognition of the need 
for standardizing outcome sets for trials (11) (16) (17). Although there is an extensive list of 
planned/ongoing and completed COS in the health area ‘pregnancy and childbirth’ on the 
COMET website (www.comet-initiative.org/studies/search), there is currently no published 
COS for FGR. This study fills that deficit. Effective dissemination will now be required to 
ensure uptake of the COS. Dissemination through the CROWN initiative will enable us to 
disseminate widely to the relevant community (17). We hope that our COS for FGR will be 
adopted into future clinical trials with the ultimate goal of informing clinical practice. 
The number of survey rounds varies across COS development procedures with most 
containing 2 or 3 rounds (18). We decided to have 3 rounds due to the number of outcomes 
presented, and believe that this number of iterations was necessary.  
While the modified Delphi process allowed participants to consider the importance of the 
outcomes independently, the consensus meeting provided an opportunity for collaborative 
discussion to reach consensus on the outcomes. The equal representation of stakeholder 
groups across the participants ensured that the meeting was collaborative and inclusive and 
the voice of the public was not overshadowed by that of research academics and 
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practitioners, and anonymous electronic voting was used.  Participants were measured and 
reasonable in searching for acceptable compromises to reach consensus.  
Strengths and limitations 
We used COMET guidance (13) (19) to inform our methodological choices when developing 
this COS. The process employed (literature review, modified Delphi survey and consensus 
meeting) is a well-established and widely-used consensus process. However, we do 
acknowledge that methods to develop COS vary (20) and there are limitations in the 
evidence underlying the methodology. For example, no validation step is recommended in 
the process to ask the stakeholders who completed round 3 whether they agree or not with 
the final COS.  
The initial long-list of outcomes presented in the survey was derived from a comprehensive 
search of the relevant literature. We adhered to standard systematic searching and 
selection strategies. We limited our search to published clinical trials and systematic reviews 
of trials as our timelines did not allow review of qualitative research studies. In addition we 
only included English language papers as we did not have the resources for translating non-
English papers. However, we believe that given the large number of papers reviewed, and 
the large, international panel of participants who were able to add outcomes as part of the 
open questions of the survey, the likelihood of missing relevant outcomes is very small. The 
fact that no additional outcomes were added to round 2 strengthened the value of this 
approach. We acknowledge these pragmatic decisions as potential limitations. 
We identified key stakeholders to capture a representative and diverse range of opinions. 
This is important to ensure that the outcomes included in the resulting COS are relevant, 
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applicable, important and acceptable to those affected by FGR (21) (22) (23) (24). Including 
members of the public presents unique challenges (25); so, although an acceptable number 
of maternity service users initially registered to take part, a relatively small number 
completed all three rounds of the survey. However, their contribution was rich, generous, 
insightful and very well informed and they were equally and fairly represented at the 
consensus meeting. We are convinced, following our engagement with members of the 
public that their involvement in COSGROVE was meaningful, important and relevant. 
Another aspect of diversity is ensuring geographical representation. It is recognized that 
internationally developed core outcome sets have more validity and are easier to 
implement into clinical research worldwide (9). Because of this, we were not only mindful of 
the total number of participants (13) (26), but also ensured a “global” coverage of opinions. 
 
Interpretation 
The final COS contains 22 outcomes to be measured in all future trials in FGR. We 
acknowledge that considering that, this is a minimum amount of outcomes to be reported it 
may be considered excessive. This is an unavoidable feature of this particular clinical area 
which represents outcomes for both mother and baby. This is consistent with other core 
outcome sets in women’s and newborn health with outcome numbers varying considerably 
from 11 to 48 (27).  The outcomes are divided into a more manageable number within the 
maternal, fetal, neonatal and childhood domains. In addition, many of the outcomes are 
overlapping. For example, gestational age, preterm birth and extremely preterm birth are 
reported separately. This reflects the independent importance of the distribution of 
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gestational age in a study population and also the proportion of preterm (or extremely 
preterm) births. This is an example of an easy win: these proportions can be readily 
calculated by researchers of primary studies, but are impossible to work out without access 
to individual data. By reporting them in primary studies, data synthesis is facilitated 
enormously. There is also overlap between outcomes and baseline characteristics. As an 
example, pre-eclampsia may be a baseline characteristic in one study and an outcome in the 
same study or another. This is, indeed, reflected by the fact that hypertensive disorders of 
pregnancy are also in the previously defined Minimum Reporting Set (8). Obviously, 
different interventions (e.g. early delivery) may also reduce the co-appearance of pre-
eclampsia and its morbidities.   
Long-term follow-up outcomes included in this COS may present difficulties for some trials. 
However, the consensus was that studies must examine not only short-term neonatal 
outcomes but also long-term development (28). It is notable that most research funding is 
limited to 2-3 year programs; in perinatal health this is incompatible with best practice: as 
an example, measuring childhood outcomes following interventions given in early 
pregnancy means a longer term approach is needed. We hope that the views expressed by 
our international group of stakeholders will translate into research practice by encouraging 
funders to look beyond the short-term and allow for the design of trials that ensure long-
term follow up, even if these are not reported on in the initial publications. A good example 
of this is the TRUFFLE trial where initial short-term outcomes were published as a cohort, 
and the primary outcome of long-term follow when this became available later (29) (30). 
COSGROVE has been developed to guide researchers on what to measure; however, it does 
not tell researchers how to measure or when to measure, and further work will be required 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
18 
 
to determine the most appropriate approach. We acknowledge that there may be outcomes 
in our COS that require further research work around broader definitions. Some of the 
outcomes are well defined in the literature and have a recognised method on ‘how’ to 
measure (e.g., HIE staging), while others do not (e.g., need for resuscitation). 
Conclusion  
International research collaboration is needed to achieve progress in improving outcomes of 
mothers and their children. Although adverse outcomes in pregnancy are catastrophic, they 
are fortunately rare. This means that studies need to be large, and data synthesis of 
individual trials is a key component needed to advance our field. This challenge can only be 
met if there is agreement and standardization of definitions, exposures and outcomes. We 
have gathered an international group of stakeholders to agree upon and standardize the 
core set of outcomes that, as a minimum, should be collected in all future trials in FGR. We 
call on funders, researchers and the scientific community to adopt COSGROVE into future 
clinical trials in FGR with the ultimate goal of improving health outcomes. 
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Table 1: Final COS to be included in all studies of FGR 
Domain Outcome Retained by Consensus (22) 
Maternal   Preeclampsia 
   Eclampsia 
  Maternal mortality (death) 
   Mode of birth 
Fetal   Stillbirth/livebirth 
Neonatal   Gestational age at birth 
   Preterm birth (delivery before 37 weeks’ 
gestation) 
   Extremely preterm birth (delivery before 28 
weeks’ gestation) 
   Birth weight 
   Birth weight less than the 10th percentile 
   Birth weight less than the 3rd percentile 
   Need for mechanical ventilation 
   Bronchopulmonary dysplasia/ Chronic lung 
disease 
   Necrotizing enterocolitis 
   Neonatal seizures 
   Hypoxic Ischemic Encephalopathy 
   Neonatal death 
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Childhood   Cognitive impairment 
   Motor impairment  
   Cerebral palsy 
   Hearing Impairment 
  Visual Impairment 
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Supplementary Table 1(S1): FGR outcomes presented in the Delphi Survey 
Domain Outcome 
1: Maternal outcomes  
1.1: Maternal disease 
pregnancy related 
Pregnancy (gestational) hypertension 
 Preeclampsia 
 HELLP Syndrome 
 Eclampsia 
 Renal impairment 
 Development of thrombotic disease 
 Abnormal Uterine Artery Doppler  
 Placental abruption  
1.2:  Maternal care needs Admission to high dependency unit (HDU) or intensive care unit 
(ICU)      
 Length of hospital stay      
 Cost of hospital stay      
 Days from diagnosis to delivery 
1.3: Maternal delivery 
outcomes  
Induction of Labour 
 Mode of birth 
 Maternal mortality (death) 
1.4:  Maternal Postpartum hemorrhage 
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postpartum outcomes 
 Postpartum infection  
1.5: Maternal 
biochemical values 
Abnormal serum biomarkers (e.g. antigenic factors, placental 
growth factor, HCG, Pregnancy-associated plasma protein-A) 
1.6: Placental findings Placental weight 
 Abnormal placental histology  
 Birthweight: placental weight ratio 
2: Fetal/neonatal 
outcomes 
 
2.1: Fetal ultrasound 
findings 
Abnormal biophysical profile score 
 Abnormal fetal Doppler assessment 
 Oligohydramnios  
2.2: Fetal outcomes Abnormal fetal scalp pH in Labour  
 Abnormal CTG during Labour 
 Miscarriage 
 Stillbirth 
 Intrapartum death 
 Meconium stained amniotic fluid 
2.3: Neonatal birth 
outcomes 
Livebirth 
 Apgar score at 5 min 
 Apgar score at 10 min 
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 Abnormal umbilical cord blood gases 
 Gestational age at birth 
 Preterm birth (delivery before 37 weeks’ gestation)  
 Extremely preterm birth (delivery before 28 weeks’ gestation) 
 Birth weight 
 Birth weight less than the 10th percentile 
 Birth weight less than the 5th percentile 
 Birth weight less than the 3rd percentile 
 Low birthweight (LBW) 
 Very low birthweight (VLBW)  
 Extremely low birth weight (ELBW)  
 Birth length 
 Head Circumference 
 Growth restriction of the newborn 
2.4:  Neonatal Care 
Outcomes 
Length of hospital stay  
 Admission to high dependency (SCBU) or intensive care unit 
(NICU)      
 Length of high dependency (SCBU) or intensive care unit 
(NICU)stay  
 Cost of hospital stay     
 Readmission after discharge home 
2.5: Neonatal immediate Need for neonatal resuscitation 
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and short-term outcomes 
 Need for any non-invasive respiratory support  
 Intubation 
 Need for mechanical ventilation 
 Need for surfactant  
 Respiratory Distress Syndrome 
 Bronchopulmonary dysplasia/ Chronic lung disease 
 Neonatal sepsis  
 Necrotizing enterocolitis  
 Neonatal seizures 
 Abnormal Thompson/Sarnat score 
 Hypoxic Ischemic Encephalopathy 
 Need for therapeutic hypothermia (cooling) 
 Hyperbilirubinaemia requiring intervention 
 Hypoglycemia  
 Hypothermia    
 Thrombocytopenia  
 Periventricular leukomalacia 
 Intraventricular Hemorrhage 
 Patent ductus arteriosus 
 Retinopathy of prematurity 
 Feeding Difficulties requiring supplemental enteral feeding  
 Feeding Difficulties requiring supplemental parenteral feeding   
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 Circulatory dysfunction requiring pressor support 
 Hypothyroidism requiring substitution treatment 
 Discharge weight   
 Fat mass at discharge 
 Congenital anomalies 
 Chromosomal malformations 
 Neonatal death 
 Exclusive breast-feeding 
2.6: Neonatal long-term 
outcomes  
Accelerated growth 
 Body Mass Index (BMI) 
 Waist circumference 
 Ponderal index measurements 
 Childhood fat mass / body composition 
 Bayley Scales of infant development  
2.7: Neonatal neurologic 
developmental outcomes 
Cognitive impairment      
 Motor impairment (excluding cerebral palsy)      
 Cerebral palsy 
 Deafness      
 Blindness      
 Need for special educational support 
 Executive function 
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 Mental illness 
 Attention-deficit hyperactivity disorder 
3. Patient-reported 
outcomes 
Maternal satisfaction with care      
 Difficulties in maternal and child bonding 
 Maternal Post-traumatic stress disorder (PTSD)      
 Maternal Depression   
 Maternal Anxiety 
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Supplementary Table 2 (S2): Outcomes removed or combined at the consensus meeting 
 Outcome Removed by Consensus (14) 
Maternal   HELLP Syndrome 
Fetal   Abnormal fetal Doppler assessment 
  Intrapartum death (Combined with Stillbirth) 
Neonatal   Umbilical cord blood gases 
   Apgar score at 5 min 
 Admission to high dependency (SCBU) or 
intensive care unit (NICU) 
   Birth weight less than the 5th percentile 
  Need for neonatal resuscitation 
   Respiratory Distress Syndrome 
   Neonatal sepsis 
   Periventricular leukomalacia 
   Intraventricular Hemorrhage 
   Congenital anomalies 
   Chromosomal malformations 
 
